Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration

Daisuke Tsugawa, Yuki Oya, Ryota Masuzaki, Kevin Ray, Darren W. Engers, Martin Dib, Nhue Do, Kaori Kuramitsu, Karen Ho, Audrey Frist, Paul B. Yu, Kenneth D. Bloch, Craig W. Lindsley, Corey R Hopkins, Charles C. Hong, Seth J. Karp

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pharmacologic agents to enhance liver regeneration after injury would have wide therapeutic application. Based on previous work suggesting inhibition of bone morphogenetic protein (BMP) signaling stimulates liver regeneration, we tested known and novel BMP inhibitors for their ability to accelerate regeneration in a partial hepatectomy (PH) model. Compounds were produced based on the 3,6-disubstituted pyrazolo[1,5-a] pyrimidine core of the BMP antagonist dorsomorphin and evaluated for their ability to inhibit BMP signaling and enhance liver regeneration. Antagonists of the BMP receptor activin receptor -like kinase 3 (ALK3), including LDN-193189 (LDN; 4-[6-[4-(1-piperazinyl) phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline), DMH2 (4-(2-(4-(3-(quinolin-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine; VU0364849), and the novel compound VU0465350 (7-(4- isopropoxyphenyl)-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine; VU5350), blocked SMAD phosphorylation in vitro and in vivo, and enhanced liver regeneration after PH. In contrast, an antagonist of the BMP receptor ALK2, VU0469381 (5-(6-(4-methoxyphenyl)pyrazolo[1,5-a] pyrimidin-3-yl)quinolone; 1LWY), did not affect liver regeneration. LDN did not affect liver synthetic or metabolic function. Mechanistically, LDN increased serum interleukin-6 levels and signal transducer and activator of transcription 3 phosphorylation in the liver, and modulated other factors known to be important for liver regeneration, including suppressor of cytokine signaling 3 and p53. These findings suggest that inhibition of ALK3 may be part of a therapeutic strategy for treating human liver disease.

Original languageEnglish (US)
Pages (from-to)549-558
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume351
Issue number3
DOIs
StatePublished - Dec 1 2014

Fingerprint

Type I Bone Morphogenetic Protein Receptors
Liver Regeneration
Bone Morphogenetic Proteins
Bone Morphogenetic Protein Receptors
Hepatectomy
Phosphorylation
STAT3 Transcription Factor
Liver
Quinolones
Liver Diseases
Regeneration
Interleukin-6
Cytokines
Wounds and Injuries
Therapeutics
Serum

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Tsugawa, D., Oya, Y., Masuzaki, R., Ray, K., Engers, D. W., Dib, M., ... Karp, S. J. (2014). Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. Journal of Pharmacology and Experimental Therapeutics, 351(3), 549-558. https://doi.org/10.1124/jpet.114.216903

Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. / Tsugawa, Daisuke; Oya, Yuki; Masuzaki, Ryota; Ray, Kevin; Engers, Darren W.; Dib, Martin; Do, Nhue; Kuramitsu, Kaori; Ho, Karen; Frist, Audrey; Yu, Paul B.; Bloch, Kenneth D.; Lindsley, Craig W.; Hopkins, Corey R; Hong, Charles C.; Karp, Seth J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 351, No. 3, 01.12.2014, p. 549-558.

Research output: Contribution to journalArticle

Tsugawa, D, Oya, Y, Masuzaki, R, Ray, K, Engers, DW, Dib, M, Do, N, Kuramitsu, K, Ho, K, Frist, A, Yu, PB, Bloch, KD, Lindsley, CW, Hopkins, CR, Hong, CC & Karp, SJ 2014, 'Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration', Journal of Pharmacology and Experimental Therapeutics, vol. 351, no. 3, pp. 549-558. https://doi.org/10.1124/jpet.114.216903
Tsugawa, Daisuke ; Oya, Yuki ; Masuzaki, Ryota ; Ray, Kevin ; Engers, Darren W. ; Dib, Martin ; Do, Nhue ; Kuramitsu, Kaori ; Ho, Karen ; Frist, Audrey ; Yu, Paul B. ; Bloch, Kenneth D. ; Lindsley, Craig W. ; Hopkins, Corey R ; Hong, Charles C. ; Karp, Seth J. / Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. In: Journal of Pharmacology and Experimental Therapeutics. 2014 ; Vol. 351, No. 3. pp. 549-558.
@article{d7ab3948bdac44718403fda53763dad1,
title = "Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration",
abstract = "Pharmacologic agents to enhance liver regeneration after injury would have wide therapeutic application. Based on previous work suggesting inhibition of bone morphogenetic protein (BMP) signaling stimulates liver regeneration, we tested known and novel BMP inhibitors for their ability to accelerate regeneration in a partial hepatectomy (PH) model. Compounds were produced based on the 3,6-disubstituted pyrazolo[1,5-a] pyrimidine core of the BMP antagonist dorsomorphin and evaluated for their ability to inhibit BMP signaling and enhance liver regeneration. Antagonists of the BMP receptor activin receptor -like kinase 3 (ALK3), including LDN-193189 (LDN; 4-[6-[4-(1-piperazinyl) phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline), DMH2 (4-(2-(4-(3-(quinolin-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine; VU0364849), and the novel compound VU0465350 (7-(4- isopropoxyphenyl)-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine; VU5350), blocked SMAD phosphorylation in vitro and in vivo, and enhanced liver regeneration after PH. In contrast, an antagonist of the BMP receptor ALK2, VU0469381 (5-(6-(4-methoxyphenyl)pyrazolo[1,5-a] pyrimidin-3-yl)quinolone; 1LWY), did not affect liver regeneration. LDN did not affect liver synthetic or metabolic function. Mechanistically, LDN increased serum interleukin-6 levels and signal transducer and activator of transcription 3 phosphorylation in the liver, and modulated other factors known to be important for liver regeneration, including suppressor of cytokine signaling 3 and p53. These findings suggest that inhibition of ALK3 may be part of a therapeutic strategy for treating human liver disease.",
author = "Daisuke Tsugawa and Yuki Oya and Ryota Masuzaki and Kevin Ray and Engers, {Darren W.} and Martin Dib and Nhue Do and Kaori Kuramitsu and Karen Ho and Audrey Frist and Yu, {Paul B.} and Bloch, {Kenneth D.} and Lindsley, {Craig W.} and Hopkins, {Corey R} and Hong, {Charles C.} and Karp, {Seth J.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1124/jpet.114.216903",
language = "English (US)",
volume = "351",
pages = "549--558",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration

AU - Tsugawa, Daisuke

AU - Oya, Yuki

AU - Masuzaki, Ryota

AU - Ray, Kevin

AU - Engers, Darren W.

AU - Dib, Martin

AU - Do, Nhue

AU - Kuramitsu, Kaori

AU - Ho, Karen

AU - Frist, Audrey

AU - Yu, Paul B.

AU - Bloch, Kenneth D.

AU - Lindsley, Craig W.

AU - Hopkins, Corey R

AU - Hong, Charles C.

AU - Karp, Seth J.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Pharmacologic agents to enhance liver regeneration after injury would have wide therapeutic application. Based on previous work suggesting inhibition of bone morphogenetic protein (BMP) signaling stimulates liver regeneration, we tested known and novel BMP inhibitors for their ability to accelerate regeneration in a partial hepatectomy (PH) model. Compounds were produced based on the 3,6-disubstituted pyrazolo[1,5-a] pyrimidine core of the BMP antagonist dorsomorphin and evaluated for their ability to inhibit BMP signaling and enhance liver regeneration. Antagonists of the BMP receptor activin receptor -like kinase 3 (ALK3), including LDN-193189 (LDN; 4-[6-[4-(1-piperazinyl) phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline), DMH2 (4-(2-(4-(3-(quinolin-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine; VU0364849), and the novel compound VU0465350 (7-(4- isopropoxyphenyl)-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine; VU5350), blocked SMAD phosphorylation in vitro and in vivo, and enhanced liver regeneration after PH. In contrast, an antagonist of the BMP receptor ALK2, VU0469381 (5-(6-(4-methoxyphenyl)pyrazolo[1,5-a] pyrimidin-3-yl)quinolone; 1LWY), did not affect liver regeneration. LDN did not affect liver synthetic or metabolic function. Mechanistically, LDN increased serum interleukin-6 levels and signal transducer and activator of transcription 3 phosphorylation in the liver, and modulated other factors known to be important for liver regeneration, including suppressor of cytokine signaling 3 and p53. These findings suggest that inhibition of ALK3 may be part of a therapeutic strategy for treating human liver disease.

AB - Pharmacologic agents to enhance liver regeneration after injury would have wide therapeutic application. Based on previous work suggesting inhibition of bone morphogenetic protein (BMP) signaling stimulates liver regeneration, we tested known and novel BMP inhibitors for their ability to accelerate regeneration in a partial hepatectomy (PH) model. Compounds were produced based on the 3,6-disubstituted pyrazolo[1,5-a] pyrimidine core of the BMP antagonist dorsomorphin and evaluated for their ability to inhibit BMP signaling and enhance liver regeneration. Antagonists of the BMP receptor activin receptor -like kinase 3 (ALK3), including LDN-193189 (LDN; 4-[6-[4-(1-piperazinyl) phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline), DMH2 (4-(2-(4-(3-(quinolin-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine; VU0364849), and the novel compound VU0465350 (7-(4- isopropoxyphenyl)-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine; VU5350), blocked SMAD phosphorylation in vitro and in vivo, and enhanced liver regeneration after PH. In contrast, an antagonist of the BMP receptor ALK2, VU0469381 (5-(6-(4-methoxyphenyl)pyrazolo[1,5-a] pyrimidin-3-yl)quinolone; 1LWY), did not affect liver regeneration. LDN did not affect liver synthetic or metabolic function. Mechanistically, LDN increased serum interleukin-6 levels and signal transducer and activator of transcription 3 phosphorylation in the liver, and modulated other factors known to be important for liver regeneration, including suppressor of cytokine signaling 3 and p53. These findings suggest that inhibition of ALK3 may be part of a therapeutic strategy for treating human liver disease.

UR - http://www.scopus.com/inward/record.url?scp=84908290446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908290446&partnerID=8YFLogxK

U2 - 10.1124/jpet.114.216903

DO - 10.1124/jpet.114.216903

M3 - Article

VL - 351

SP - 549

EP - 558

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -